REM sleep behavior disorder (RBD) is strongly associated with development of Parkinson’s Disease and other α-synuclein-related disorders. Dopamine transporter (DAT) binding deficit predicts conversion to α-synuclein-related disorders in individuals with RBD. In turn, identifying which individuals with RBD have the highest likelihood of having abnormal DAT binding would be useful. The objective of this analysis was to examine if there are basic clinical predictors of DAT deficit in RBD. Participants referred for inclusion in the RBD cohort of the Parkinson Progression Markers Initiative were included. Assessments at the screening visit including DAT SPECT imaging, physical examination, cognitive function screen, and questionnaire-based non-motor assessment. The group with DAT binding deficit (n = 49) was compared to those without (n = 26). There were no significant differences in demographic or clinical features between the two groups. When recruiting RBD cohorts enriched for high risk of neurodegenerative disorders, our data support the need for objective biomarker assessments.

REM睡眠行为障碍（RBD）与帕金森氏病和其他α-突触核蛋白相关疾病的发展密切相关。多巴胺转运蛋白（DAT）结合缺陷可预测RBD患者转化为α-突触核蛋白相关疾病。反过来，确定哪些具有RBD的个体具有异常DAT结合的可能性最高。该分析的目的是检查RBD中是否存在DAT缺乏的基本临床预测指标。被纳入帕金森进阶标记计划RBD队列的参与者也包括在内。筛查访视时的评估包括DAT SPECT成像，体格检查，认知功能筛查和基于问卷的非运动评估。DAT结合缺陷组（n = 49）与没有（n  = 26）的人进行了比较。两组之间的人口统计学或临床特征无显着差异。当招募丰富的RBD队列以应对神经退行性疾病的高风险时，我们的数据支持对客观生物标志物评估的需求。